

23
24
25
26
27
28
29
30
31
32
33
34
35

Key Points

Question: Can a large regional health system leverage the electronic health record to analyze hypertension trends and disparities to drive improvement?

Findings: We analyzed 1,376,325 patients over 12 years and found that age-adjusted hypertension prevalence increased by approximately 5%. Age-adjusted hypertension control rates were in the 70% range and remained stable. Non-Hispanic Black patients represented 25% of our specific regional population and had 12-14% higher hypertension prevalence rates, higher mean age-adjusted systolic and diastolic blood pressure, and lower hypertension control rates compared with other racial groups.

Meaning: Real world data can provide actionable insights about hypertension and disparities in a specific region that could inform regional system strategies and initiatives for improvement.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Abstract

Background: The digital transformation of medical data enables health systems to leverage real-world data (RWD) from electronic health records (EHR) to gain actionable insights for improving hypertension care.

Methods: We performed a serial cross-sectional analysis of outpatients of a large regional health system from 2010 to 2021. Hypertension was defined by systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg or recorded treatment with anti-hypertension medications. We evaluated four methods of using blood pressure measurements in the EHR to define hypertension.

The primary outcomes were age-adjusted prevalence rates and age-adjusted control rates. Secondary outcomes were age-adjusted mean SBP and DBP and age-adjusted proportion of patients with a searchable diagnosis code of hypertension in the EHR.

Results: Hypertension prevalence varied depending on the definition used, ranging from 36.5% to 50.9% initially and increasing over time by approximately 5%, regardless of the definition used. Control rates ranged from 61.2% to 71.3% initially, rose during 2018-2019 and fell during 2020-2021. The proportion of patients with a hypertension diagnosis ranged from 45.5% to 60.2% initially and improved during the study period. Non-Hispanic Black patients represented 25% of our regional population and consistently had higher prevalence rates, higher mean SBP and DBP and lower control rates compared with other racial and ethnic groups.

Conclusion: In a large regional health system, we leveraged the EHR to provide real-world insights. The findings largely reflected national trends but showed distinctive regional demographics and findings. The findings have provided opportunities for improvement, with

- 58 prevalence increasing, a quarter of the patients not controlled, and marked disparities. This
- 59 approach could be emulated by regional health systems seeking to improve hypertension care.

1 **Introduction**

2 Hypertension is a persistent and challenging health problem in the United States,
3 estimated to affect almost half of adult Americans.¹ Of patients with hypertension, approximately
4 half have uncontrolled blood pressure (BP),² which disproportionately affects African
5 Americans.²⁻⁴ Improving the detection and treatment hypertension is a national priority and
6 offers an important opportunity to modify the risk for cardiovascular disease and stroke and to
7 address a major racial disparity.⁵

8 A 2014 advisory from the American College of Cardiology, American Heart Association
9 and the US Centers for Disease Control and Prevention called for health system approaches for
10 addressing hypertension.⁶ System-wide strategies, along with improvements at the clinician and
11 patient level, could help optimize BP control and effectively modify the risk associated with
12 hypertension.^{6,7} To help design health system strategies, more information is needed to
13 characterize hypertension trends and identify opportunities for improvement at the regional
14 health system level, ideally utilizing readily available real-world evidence from the electronic
15 health record (EHR) systems.

16 There are opportunities to broaden the ways a regional health system might use EHR data
17 to investigate hypertension. Converting EHR data into a common data model can provide a more
18 agile analytical platform, which could enable a health system to take advantage of their long-
19 term data, explore various analytical methods, and evaluate trends and demographics that may be
20 unique to a health system's region. Analysis of data at the regional level could enable customized
21 regional initiatives to improve hypertension care.

22 Accordingly, we leveraged the EHR from a large health system caring for a diverse
23 population to evaluate performance in the care of patients with hypertension.⁸ EHR data over 12

24 years were transformed into a harmonized and validated data set that has enabled a serial cross-
25 sectional analysis of hypertension in a large regional population.⁹ We specifically sought to
26 identify trends using various operational hypertension definitions to investigate disparities and
27 opportunities for improvement.

28 **Methods**

29 **Data Source**

30 This retrospective observational study was performed at a large non-profit integrated
31 healthcare system in Virginia and Northeastern North Carolina. The system began using a
32 centralized EHR system designed by the Epic Corporation in 2007. In 2021, the health system
33 began extracting key clinical data from its EHR and transforming the data into a harmonized data
34 platform using the Observational Medical Outcomes Partnership (OMOP) common data model
35 version 5.3.⁹

36 **Study Population**

37 The overall study population consisted of all adult patients (≥ 18 years old) who had at
38 least 1 outpatient blood pressure reading recorded between January 1st, 2010, and December
39 31st, 2021. Emulating the NHANES study,² we conducted a serial cross-sectional study by
40 independently analyzing the data in 2-year cycles from 2010-2011 to 2020-2021. In contrast to
41 the defined clinical protocols of NHANES, our real-world data approach required defining
42 computational protocols to analyze recorded BP readings in the EHR to create operational
43 definitions of hypertension.

44 BP readings were first analyzed at the visit level. If more than one BP reading was taken
45 during a visit, the first reading was disregarded and the mean of the remaining BP readings from
46 the visit defined the visit BP measurement. If multiple outpatient visits occurred for a patient on

47 a specific date, we calculated the mean of the visit BP measurements and used the mean as the
48 visit BP measurement for that date.

49 **Definition of Hypertension**

50 In each 2-year cycle, a patient was classified as having hypertension according to the
51 definitions listed below using either an elevated visit BP measurement, or use of at least one first
52 line anti-hypertension medication recorded during the 2-year cycle, like NHANES.² BP elevation
53 was defined as a systolic blood pressure (SBP) ≥ 140 mm Hg, or diastolic blood pressure (DBP)
54 ≥ 90 mm Hg. First-line anti-hypertension medications were defined according to the 2017
55 AHA/ACC hypertension guideline¹⁰ and are listed with their associated OMOP concept
56 identification numbers in eTable 1.

57 We evaluated four operational hypertension definitions using four different methods for
58 incorporating recorded BP measurement into the definition: 1) using at least one elevated visit
59 BP measurement during a 2-year cycle, 2) using the first visit BP measurement during a 2-year
60 cycle, 3) using a single randomly chosen visit BP measurement during a 2-year cycle, or 4) using
61 at least two elevated visit BP measurements during a 2-year cycle. Our rationale for using these
62 different operational hypertension definitions was to provide definitions that are comparable with
63 other studies and guideline recommendations. For example, our third definition would be
64 comparable to the NHANES study,² and our fourth definition would be comparable to the
65 generally accepted guideline definition.¹⁰

66

67 **Definitions of Outcomes**

68 Primary outcomes were age-adjusted hypertension prevalence and age-adjusted rates of
69 BP control during each 2-year cycle. BP control was defined at the patient level as a mean SBP <

70 140 mmHg and mean DBP < 90 mmHg during a 2-year cycle. To adjust for differences in age
71 distribution among the 2-year study cycles, direct standardization was employed using two
72 different standards. For age-adjustment of hypertension prevalence and average BP, the standard
73 was the average age distribution of all adults across all study cycles, while for age-adjustment of
74 other outcome measures, the standard was average age distribution of adults with hypertension
75 across all study cycles. The age categories used for standardization were: 18-44 years, 45-64
76 years, 65-74 years, and 75 years or older. The proportions used for age-adjustment of all patients
77 and of hypertension patients for each operational hypertension definition are listed in eTable 2.

78 Secondary outcome measures were the age-adjusted mean SBP and DBP for all patients
79 and for hypertensive patients, and the age-adjusted proportions of patients who were labelled
80 with a searchable diagnosis code of hypertension in the EHR during a 2-year cycle. The coded
81 diagnoses of hypertension and the corresponding OMOP concept identification numbers listed in
82 eTable 3).

83

84 **Statistical Analysis**

85 Descriptive statistics were used to characterize the overall study population and the
86 populations from each 2-year cycle, and graphical representations were used to demonstrate
87 temporal trends. The generalized estimation equation (GEE) method was applied to assess the
88 predictors of different outcomes while accounting for the fact that multiple observations might
89 have been available for the same individuals at different cycles. Specifically, an exchangeable
90 within-person working correlation structure was specified in each GEE model and 95%
91 confidence intervals were calculated using a robust variance estimator. Models used to evaluate
92 dichotomous outcomes included a specification for the binomial distribution of the dependent

93 variable, and models used to evaluate continuous outcomes included a specification for the
94 Gaussian distribution of the dependent variable. The independent variables included cycle, sex,
95 race and ethnicity, and age group, and each variable was treated as categorical in the GEE model.
96 To simplify the analysis and avoid multiple comparisons, in the GEE modeling section, we only
97 used the operational hypertension definition that used BP measurement from a single randomly
98 chosen visit during a 2-year cycle. All statistical tests were 2-sided, with a level of significance
99 of 0.05. Data collection using the OMOP model was conducted with the Microsoft SQL Server
100 and data analysis was performed using R (version 4.2.3). The study was approved by the
101 Institutional Review Board at Eastern Virginia Medical School. The study was reported
102 following the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)
103 reporting guidelines.¹¹

104 **Results**

105 **Population Characteristics**

106 A total of 1,376,325 unique adults met the overall study inclusion criteria. The
107 demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2-
108 year cycle was analyzed independently, and individual patients could appear in one or more 2-
109 year cycles, depending on the care they received. Thus, the number of patients in the six 2-year
110 cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The
111 numbers of outpatient visits and outpatient BP measurements per patient during a 2-year cycle
112 were relatively constant during the study period. The median number of outpatient visits per
113 patient was 2 during 2010-2011 and 3 during the remaining 2-year cycles. The median number of
114 outpatient BP measurements per patient was 5 during 2012-2013 and 2018-2019 and was 4
115 during the remaining 2-year cycles.

116 Among all patients, the mean age-adjusted SBP ranged from 125.1 to 127.0 mm Hg and
117 the mean age-adjusted DBP ranged from 74.4 to 76.0 mm Hg (Table 1). Mean SBP and DBP
118 among all patients showed an upward trend during the time of study.

119

120 **Hypertension Prevalence and Disparities**

121 The demographics of the hypertensive patients varied slightly depending on the
122 operational hypertension definition. The demographics of hypertensive patients (using the
123 random BP measurement definition, which is comparable to the NHANES study) are shown in
124 eTable 4.

125 The age-adjusted hypertension prevalence rates over the 12-year study period for each
126 operational hypertension definition are shown in Figure 1. Depending on the operational
127 hypertension definition, the hypertension prevalence rates ranged from 36.5% to 50.9% and
128 prevalence increased by about 5% over the study period regardless of the operational
129 hypertension definition.

130 Non-Hispanic Black patients consistently showed 12-14% higher age-adjusted
131 hypertension prevalence rates compared with the non-Hispanic White patients (OR 2.03, [2.02,
132 2.04], $P < 0.001$, Figure 2). Hypertension prevalence rates were progressively higher by age
133 group, peaking at 80% in patients >75 years old during 2020-2021 (eFigure 1). Men consistently
134 showed approximately 7% higher hypertension prevalence rates (OR 1.41, [1.40, 1.42], P
135 < 0.001 , eFigure 2).

136 The proportions of hypertensive patients defined by elevated BP only, by use of a first-
137 line antihypertensive medication only, or by both are shown in eFigure3. For all operational

138 hypertension definitions, the proportions of hypertensive patients defined by medication usage or
139 combination of medication usage and elevated BP increased during the study period.

140

141 **Blood Pressure Control Rates Among Patients with Hypertension and Disparities**

142 Among patients with hypertension, the age-adjusted BP control rates during the study
143 period ranged from 61.2% to 73.3%, depending on the operational hypertension definition
144 (Figure 3). The trend in BP control rates exhibited an initial increase from 2010-2011 to 2014-
145 2015, followed by a decline in 2016-2017. Thereafter, the control rates rose again from 2018-
146 2019, only to decline once more in 2020-2021. The age-adjusted BP control rates were
147 consistently about 3% lower in men (OR 0.89, [0.88, 0.90], $P < 0.001$, eFigure 4) and consistently
148 about 5-7% lower in non-Hispanic Black patients as compared with non-Hispanic White patients
149 (OR 0.77, [0.76, 0.78], $P < 0.001$, eFigure 5).

150 Among hypertension patients, the mean age-adjusted SBP ranged from 132.3 to 135.4
151 mmHg and mean age-adjusted DBP ranged from 76.8 to 78.8 mmHg (eFigure 6). Mean BP was
152 relatively unchanged during the study timeframe regardless of the operational hypertension
153 definition. Age-adjusted mean BP was consistently higher in non-Hispanic Black patients as
154 compared with other non-Hispanic White patients (SBP: +2.61 [2.55, 2.67]; DBP: +1.31 [1.28,
155 1.35]; $P < 0.001$ for both, eFigure 7).

156

157 **Coded Diagnosis Rates Among Patients with Hypertension and Disparities**

158 Among patients with hypertension, the age-adjusted proportion of patients labelled in the
159 EHR with a coded diagnosis of hypertension ranged from 45.5% to 68.6%, again depending on
160 the operational hypertension definition (Figure 4). The proportion of patients diagnosed with

161 hypertension, as indicated by coded diagnoses, exhibited an initial increase from 2010-2011 to
162 2014-2015, followed by a decline in 2016-2017. Thereafter, the proportions rose again in 2020-
163 2021. The proportion of patients with a coded diagnosis of hypertension was highest in
164 hypertension groups defined by 2 or more BP measurements than in groups defined by the other
165 definitions. The proportion of patients with hypertension with a coded diagnosis of hypertension
166 was similar in women and men. Rates of receiving a coded diagnosis were consistently about 5%
167 higher in non-Hispanic Black patients (OR 1.26 [1.25, 1.27], $P<0.001$) and Asian patients (OR
168 1.31 [1.28, 1.35], $P<0.001$), compared with White and Hispanic patients (eFigure 8).

169

170

171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192

Discussion

In this serial cross-sectional study, we leveraged EHRs of a large health system to analyze regional trends in hypertension using various operational hypertension definitions. We showed a marked increase in age-adjusted hypertension prevalence rates, modest age-adjusted BP control rates, and relatively low but upwardly trending age-adjusted rates of coding hypertension in the EHR during the 12 years of study. In addition, we noted important disparities in age-adjusted hypertension prevalence rates, age-adjusted BP control rates, and age-adjusted mean BP levels that stayed consistent over time. The age-adjusted hypertension prevalence rates were 12-14% higher in non-Hispanic Black patients, 7% higher in men, and progressively higher by age group throughout the study period.

This study demonstrates the ability to observe hypertension trends and disparities at a regional health system level using real-world data, which could greatly facilitate locally designed system-level interventions to address hypertension and racial disparities. We were able to create an agile analytical data platform that enabled a comparison of a variety of operational hypertension definitions and an evaluation of how age, sex, and race/ethnicity affect hypertension trends. Our analytical data platform enabled examination of multiple operational hypertension definitions and we demonstrated substantial differences in outcomes, depending on the sensitivity of the hypertension definition.

Our study demonstrated a steady rise of about 5% in the age-adjusted hypertension prevalence rates throughout the study period, regardless of the operational hypertension definition. Increases in hypertension prevalence rates were seen in all age groups, both sexes, and in all race/ethnicity groups.

193 The average age of patients and the age adjusted mean SBP and DBP increased during
194 the study period, which may have contributed to the increase in hypertension prevalence rates.
195 The increase in hypertension prevalence rates did not appear to be artifactually affected by the
196 frequency of outpatient visits or BP measurements.

197 Our definition of hypertension included whether patients were prescribed first-line
198 antihypertension medications, which may have also contributed to the increase in hypertension
199 prevalence rates. The proportion of patients who were defined as hypertensive by the
200 medication-use criterion increased during the 2012-2013, 2018-2019 and 2020-2021 2-year
201 cycles, possibly due to changing guidelines for hypertension. The 2017 ACC/AHA published
202 guidelines recommended a lower BP goal which could have caused more patients to receive first-
203 line antihypertensive medications and could have affected the hypertension prevalence rates
204 during 2018-2019 and 2020-2021.¹⁰

205 The age-adjusted proportion of patients with controlled BP rose from 61-71% in 2010-
206 2011 to 64-73% in 2014-2015, fell in 2016-2017, rose again to 66-73% in 2018-2019, and fell in
207 62-68% in 2020-2021. The pattern was consistent among patients defined by all 4 operational
208 hypertension definitions. Non-Hispanic Blacks had BP control rates that were consistently about
209 5% lower than Whites. The rise in control rates in all groups during 2018-2019 could be
210 explained by the 2017 ACC/AHA guideline recommendations for tighter BP control.¹⁰ The fall
211 in control during 2020-2021 may have been caused by changes in healthcare associated with the
212 COVID-19 pandemic.

213 The proportion of patients with a coded diagnosis of hypertension among patients with
214 hypertension increased during the study period except during 2016-2017 and the trends were
215 similar in all 4 operational hypertension definition groups. There were no differences by sex.

216 Non-Hispanic Blacks and Asians were 6-10% more likely to have a coded diagnosis of
217 hypertension as compared with other race/ethnicity groups. Interestingly, non-Hispanic Black
218 patients were significantly more likely to have hypertension by all the operational hypertension
219 definitions and less likely to have BP controlled, even though they were more likely to have been
220 labelled in the EHR with a coded diagnosis of hypertension.

221 Our results from a regional health system provide supplemental information to the
222 national estimates reported by the National Health and Nutrition Examination Survey
223 (NHANES). Using a comparable operational hypertension definition (a single random visit BP
224 measurement), our age-adjusted hypertension prevalence rates are higher (41.1% to 46.1%) and
225 increased steadily as compared with NHANES which reported prevalence rates that were lower
226 and remained constant (30% to 32%).² Our BP control rates (61.2% to 65.9%) were also higher
227 than those reported by NHANES (31.8% to 53.8%). These differences may be because our study
228 population was derived from patients exposed to a healthcare system rather than subjects
229 randomly selected from the general population. Importantly, the proportion of non-Hispanic
230 Blacks in our study was roughly twice that from the NHANES study, reflecting the
231 demographics of our region, which may have increased the hypertension prevalence rates.

232 Studies have suggested that hypertension prevalence based on methods using electronic
233 health records could be underestimated.¹² In our study, we used the EHR, but we defined
234 hypertension based on measurement of BP, rather than based on the coded diagnosis of
235 hypertension, which appears to have overcome the potential of under-reporting hypertension
236 using the EHR.

237 Our hypertension control rates were similar to those reported by the PCORnet Blood
238 Pressure Control Laboratory, which reported an average BP control rate of 62%.¹³ Their findings

239 from 25 health systems showed different demographics than our regional analysis, with Black
240 patients only comprising 15% of their population, as compared to approximately 30% of the
241 hypertensive patients in our study. While nationwide studies are informative, limiting the
242 analysis to a single regional health system may provide actionable insights regarding disparities
243 that are more relevant locally, based on the demographics of that regional health system.

244 Banerjee et al measured the hypertension coding rate in 251,590 patients defined
245 hypertension by 2 or more BP readings $\geq 140/90$ mm Hg and/or antihypertensive medications
246 prescribed during the study period. Among those patients, the coded diagnosis rate was 62.9%,
247 very similar to our finding among patients with a comparable operational hypertension
248 definition.¹²

249 Our study has recognized strengths and limitations. Our approach of analyzing real-world
250 data from a single health system is practical and feasible, and the results are similar to the
251 multicenter approach of the PCORnet Blood Pressure Control Laboratory.¹⁴ Our data platform
252 allows rapid evaluation of populations at scale and could be a source of continuing evaluation
253 with planned periodic additions to the data base,^{15,16} providing a powerful tool for generating
254 actionable insights from real-world data.^{17,18} This data resource is an model of what could be a
255 useful generator of insights for a learning health system.^{19,20}

256 A possible limitation of our study, as compared with the NHANES approach,² however,
257 is that BP was obtained in the usual care setting, rather than through a rigorous protocolized
258 approach. Although clinicians expect and often demand accurate BP measurements in usual care
259 settings, the BP measurements in real-world settings may be less accurate than in the
260 protocolized setting of a prospective research study.²¹ Also, the coded diagnosis of hypertension
261 in the EHR could have been affected by recall bias and other sources of possible coding error.¹⁵

262 In conclusion, we were able to use real-world EHR data to establish hypertension
263 prevalence rates, control rates, and diagnostic coding rates in a large population using the EHR
264 from a large regional health system, showing important trends and opportunities to address racial
265 disparities. Our study may provide a model for other health systems seeking to improve
266 hypertension care at a regional health system level and may lead to further research on how to
267 use real-world data and computational approaches for addressing hypertension.

268 **Conflicts of Interest and Financial Disclosures**

269 In the past three years, Dr. Krumholz received expenses and/or personal fees from
270 UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the
271 Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baughman Law
272 Firm. He is a co-founder of Refactor Health and HugoHealth, and is associated with
273 contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid
274 Services and through Yale University from Johnson & Johnson. Dr. Brush receives royalties
275 from Dementi Milestone Publishing for the book “The Science of the Art of Medicine: A
276 Guide to Medical Reasoning.” Dr. Schulz received expenses and/or personal fees from
277 HugoHealth, Abbott, Instrumentation Laboratories, and Detect, Inc., and is a cofounder of
278 Refactor Health. The other authors report no disclosures.

279

280

281

282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303

References

1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K and Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145:e153-e639.
2. Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB and Colantonio LD. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. *JAMA*. 2020;324:1190-1200.
3. Clark D, 3rd, Colantonio LD, Min YI, Hall ME, Zhao H, Mentz RJ, Shimbo D, Ogedegbe G, Howard G, Levitan EB, Jones DW, Correa A and Muntner P. Population-Attributable Risk for Cardiovascular Disease Associated With Hypertension in Black Adults. *JAMA Cardiol*. 2019;4:1194-1202.
4. Lu Y, Wang Y, Spatz ES, Onuma O, Nasir K, Rodriguez F, Watson KE and Krumholz HM. National Trends and Disparities in Hospitalization for Acute Hypertension Among Medicare Beneficiaries (1999-2019). *Circulation*. 2021;144:1683-1693.
5. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK and He J. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and

- 304 Mortality: A Systematic Review and Network Meta-analysis. *JAMA Cardiol.*
305 2017;2:775-781.
- 306 6. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA
307 and Sanchez E. An effective approach to high blood pressure control: a science
308 advisory from the American Heart Association, the American College of Cardiology,
309 and the Centers for Disease Control and Prevention. *J Am Coll Cardiol.*
310 2014;63:1230-1238.
- 311 7. Jaffe MG, Lee GA, Young JD, Sidney S and Go AS. Improved blood pressure control
312 associated with a large-scale hypertension program. *JAMA.* 2013;310:699-705.
- 313 8. Lu Y, Huang C, Mahajan S, Schulz WL, Nasir K, Spatz ES and Krumholz HM.
314 Leveraging the Electronic Health Records for Population Health: A Case Study of
315 Patients With Markedly Elevated Blood Pressure. *J Am Heart Assoc.*
316 2020;9:e015033.
- 317 9. Hripesak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA,
318 Park RW, Wong IC, Rijnbeek PR, van der Lei J, Pratt N, Noren GN, Li YC, Stang
319 PE, Madigan D and Ryan PB. Observational Health Data Sciences and Informatics
320 (OHDSI): Opportunities for Observational Researchers. *Stud Health Technol Inform.*
321 2015;216:574-8.
- 322 10. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison
323 Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ,
324 Muntner P, Ovbiagele B, Smith SC, Jr., Spencer CC, Stafford RS, Taler SJ, Thomas
325 RJ, Williams KA, Sr., Williamson JD and Wright JT, Jr. 2017
326 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for

- 327 the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
328 Adults: A Report of the American College of Cardiology/American Heart Association
329 Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71:e127-e248.
- 330 11. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP and
331 Initiative S. The Strengthening the Reporting of Observational Studies in
332 Epidemiology (STROBE) Statement: guidelines for reporting observational studies.
333 *International journal of surgery*. 2014;12:1495-1499.
- 334 12. Banerjee D, Chung S, Wong EC, Wang EJ, Stafford RS and Palaniappan LP.
335 Underdiagnosis of hypertension using electronic health records. *Am J Hypertens*.
336 2012;25:97-102.
- 337 13. Cooper-DeHoff RM, Fontil V, Carton T, Chamberlain AM, Todd J, O'Brien EC,
338 Shaw KM, Smith M, Choi S, Nilles EK, Ford D, Tecson KM, Dennar PE, Ahmad F,
339 Wu S, McClay JC, Azar K, Singh R, Faulkner Modrow M, Shay CM, Rakotz M,
340 Wozniak G and Pletcher MJ. Tracking Blood Pressure Control Performance and
341 Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control
342 Laboratory. *J Am Heart Assoc*. 2021;10:e022224.
- 343 14. Pletcher MJ, Fontil V, Carton T, Shaw KM, Smith M, Choi S, Todd J, Chamberlain
344 AM, O'Brien EC, Faulkner M, Maeztu C, Wozniak G, Rakotz M, Shay CM and
345 Cooper-DeHoff RM. The PCORnet Blood Pressure Control Laboratory: A Platform
346 for Surveillance and Efficient Trials. *Circ Cardiovasc Qual Outcomes*.
347 2020;13:e006115.

- 348 15. Casey JA, Schwartz BS, Stewart WF and Adler NE. Using Electronic Health Records
349 for Population Health Research: A Review of Methods and Applications. *Annu Rev*
350 *Public Health*. 2016;37:61-81.
- 351 16. Schulz WL, Kvedar JC and Krumholz HM. Agile analytics to support rapid
352 knowledge pipelines. *NPJ Digit Med*. 2020;3:108.
- 353 17. Krumholz HM. Big data and new knowledge in medicine: the thinking, training, and
354 tools needed for a learning health system. *Health Aff (Millwood)*. 2014;33:1163-70.
- 355 18. Krumholz HM. Inflection Point: Ideas for Accelerating Breakthroughs and Improving
356 Cardiovascular Health. *Circ Cardiovasc Qual Outcomes*. 2020;13:e007615.
- 357 19. Greene SM, Reid RJ and Larson EB. Implementing the learning health system: from
358 concept to action. *Ann Intern Med*. 2012;157:207-10.
- 359 20. Foraker RE, Benziger CP, DeBarmore BM, Cene CW, Loustalot F, Khan Y,
360 Anderson CAM, Roger VL, American Heart Association Council on E, Prevention,
361 Council on Arteriosclerosis T, Vascular B, Council on L and Cardiometabolic H.
362 Achieving Optimal Population Cardiovascular Health Requires an Interdisciplinary
363 Team and a Learning Healthcare System: A Scientific Statement From the American
364 Heart Association. *Circulation*. 2021;143:e9-e18.
- 365 21. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG,
366 Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB and
367 Wright JT, Jr. Measurement of Blood Pressure in Humans: A Scientific Statement
368 From the American Heart Association. *Hypertension*. 2019;73:e35-e66.

369
370

371 **Table 1.** Demographic characteristics and mean systolic blood pressure (SBP) and mean
 372 diastolic blood pressure (DBP) of all patients in each 2-year cycle.

2-year Cycle	2010-2011	2012-2013	2014-2015	2016-2017	2018-2019	2020-2021
Patients	395,859	429,754	466,692	631,892	608,497	619,023
Sex						
Female	231,203 (58%)	254,610 (59%)	275,386 (59%)	370,352 (59%)	355,759 (58%)	362,140 (59%)
Male	164,625 (42%)	175,130 (41%)	191,306 (41%)	261,540 (41%)	252,736 (42%)	256,874 (41%)
Race/Ethnicity						
Non-Hispanic Black	99,779 (25%)	109,183 (25%)	122,477 (26%)	142,447 (23%)	135,880 (22%)	146,162 (24%)
Non-Hispanic White	259,665 (66%)	282,167 (66%)	305,112 (65%)	438,170 (69%)	423,892 (70%)	423,186 (68%)
Hispanic/Latino	7,342 (1.9%)	11,549 (2.7%)	13,060 (2.8%)	19,449 (3.1%)	19,691 (3.2%)	21,297 (3.4%)
Asian	7,616 (1.9%)	9,294 (2.2%)	10,406 (2.2%)	12,698 (2.0%)	12,834 (2.1%)	13,363 (2.2%)
Unknown	21,457 (5.4%)	17,561 (4.1%)	15,637 (3.4%)	19,128 (3.0%)	16,200 (2.7%)	15,015 (2.4%)
Mean Age (SD)	51.0 (18.1)	51.5 (18.2)	52.3 (18.2)	52.9 (18.4)	54.6 (18.2)	55.3 (18.2)
Age Group						
18-44	142,539 (36%)	151,749 (35%)	158,628 (34%)	210,073 (33%)	182,608 (30%)	181,485 (29%)
45-64	156,016 (39%)	165,571 (39%)	178,135 (38%)	234,314 (37%)	224,434 (37%)	221,173 (36%)
65-74	54,364 (14%)	64,801 (15%)	76,065 (16%)	109,058 (17%)	114,851 (19%)	124,125 (20%)
>75	42,940 (11%)	47,633 (11%)	53,864 (12%)	78,447 (12%)	86,604 (14%)	92,240 (15%)
Mean SBP (SD)	125.2 (14.9)	124.8 (14.8)	125.1 (14.8)	126.1 (14.8)	126.1 (14.2)	127.5 (14.6)
Mean DBP (SD)	74.7 (9.4)	74.4 (9.2)	74.7 (9.1)	75.5 (9.0)	75.3 (8.7)	75.8 (8.8)

373 SD=standard deviation


374

375

Figures

376 **Figure 1.** Age-adjusted hypertension prevalence rates in each 2-year cycle by operational

377 hypertension definition.



378


379 1BP+ = 1 elevated blood pressure (BP) measurement, 2BP+ = at least 2 elevated measurements.

380

381

382 **Figure 2.** Age-adjusted hypertension prevalence rates by race/ethnicity in each 2-year cycle by

383 operational hypertension definition.




384

385 1BP+ = 1 elevated blood pressure (BP) measurement, 2BP+ = at least 2 elevated measurements.

386

387 **Figure 3.** Age-adjusted blood pressure control rates in each 2-year cycle by operational
 388 hypertension definition.




389
 390 1BP+ = 1 elevated blood pressure (BP) measurement, 2BP+ = at least 2 elevated measurements.
 391

392

393 **Figure 4.** Age-adjusted hypertension coding rates in each 2-year cycle by operational

394 hypertension definition.



395
 396 1BP+ = 1 elevated blood pressure (BP) measurement, 2BP+ = at least 2 elevated measurements.
 397